Development of a novel PIKFYVE kinase inhibitor for the treatment of COVID-19
Grant Award Details
Grant Type:
Grant Number:
DISC2COVID19-11901
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$140,067
Status:
Closed
Progress Reports
Reporting Period:
Year 1
Grant Application Details
Application Title:
Development of a novel PIKFYVE kinase inhibitor for the treatment of COVID-19
Public Abstract:
Research Objective
Alveolar type II cells are the stem cells of the lung, and they are killed by SARS-CoV-2. We will determine if a novel PIKFYVE kinase inhibitor prevents SARS-CoV-2 infection of type II cells.
Impact
Although PIKFYVE inhibition blocks SARS-CoV-2 infection, no known PIKFYVE inhibitors have suitable drug-like properties. We would validate a novel PIKFYVE inhibitor for the treatment of COVID-19.
Major Proposed Activities
Alveolar type II cells are the stem cells of the lung, and they are killed by SARS-CoV-2. We will determine if a novel PIKFYVE kinase inhibitor prevents SARS-CoV-2 infection of type II cells.
Impact
Although PIKFYVE inhibition blocks SARS-CoV-2 infection, no known PIKFYVE inhibitors have suitable drug-like properties. We would validate a novel PIKFYVE inhibitor for the treatment of COVID-19.
Major Proposed Activities
- Confirm ASR-149’s efficacy against SARS-CoV-2 in human iPSC-lung type II cells
- Use antisense oligonucleotides to verify that PIKFYVE inhibition blocks entry of SARS-CoV-2 pseudovirus and live replication competent SARS-CoV-2 virus in human iPSC-lung type II cells
Statement of Benefit to California:
If successful, these studies could lead to an effective treatment for COVID-19 that would reduce suffering from COVID-19 and enable Californians to live without social distancing requirements.
